Boehringer Ingelheim — Biomedical Watch V2

Traitements11programmes

Essais6liés

Publications4liées

SourceDBlocale

Traitements

11

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
BI 3000202This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are put into 5 groups randomly, which means by chance. 4 groups get different doses of BI 3000202, and 1 group gets a placebo. Placebo tablets look like BI 3000202 tablets but do not contain any medicine. Participants take the tablets for 1 year. All participants also continue their regular treatment for SLE. Participants are in the study for a bit longer than 1 year. During this time, they visit the study site regularly. Doctors check the participants' health and take note of any unwanted effects. They also compare the results between the groups to see if the treatment works.	Lupus	Phase 2	À vérifier	United States, Argentina, Australia, Brazil, Bulgaria, China, Colombia, Croatia, …	À vérifier
BIIL 284 BSTo evaluate the effect of multiple doses of BIIL 284 BS on the pharmacokinetics of a single dose of theophylline.	SEP	Phase 1	À vérifier		À vérifier
EmpagliflozinThe purpose of this study is to find out what effects (good and bad) the study medications (insulin or Empagliflozin) have on adults with mild memory impairment or early Alzheimer's disease who are clinically prescribed an anti-amyloid therapy compared to placebo.	Alzheimer, Hypertension	Phase 3	À vérifier	United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, …	À vérifier
enalaprilTo compare the renal consequences of two different approaches to blocking the renin angiotensin system in subjects with hypertension and concurrent Type II diabetes mellitus and diabetic nephropathy.	Hypertension	Phase 3	À vérifier	Denmark, Finland, Netherlands, Norway, Sweden, United Kingdom	À vérifier
NerandomilastThis study is open to adults aged 18 and older who have a condition known as active idiopathic inflammatory myopathy (IIM) or myositis. People can participate if they have a specific type of myositis. The purpose of this study is to find out whether a medicine called nerandomilast improves IIM symptoms. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take nerandomilast or placebo twice a day for 1 year. Participants are in the study for about 1 year and 2 months. During this time, they visit the study site at least 16 times. During this time, doctors regularly check the participant's health, IIM symptoms, and take note of any unwanted effects. Participants fill in questionnaires about their IIM symptoms and how IIM impacts their quality of life. The results are compared between the 2 groups to see whether the treatment works.	Myopathies	Phase 3	Immunomodulation + Traitement symptomatique	United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, …	À vérifier
VicadrostatThis study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.	Hypertension	Phase 3	À vérifier	United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, …	À vérifier
EmpagliflozinThe purpose of this study is to find out what effects (good and bad) the study medications (insulin or Empagliflozin) have on adults with mild memory impairment or early Alzheimer's disease who are clinically prescribed an anti-amyloid therapy compared to placebo.	Alzheimer	Phase 2	À vérifier	United States	À vérifier
BI 3000202This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are put into 5 groups randomly, which means by chance. 4 groups get different doses of BI 3000202, and 1 group gets a placebo. Placebo tablets look like BI 3000202 tablets but do not contain any medicine. Participants take the tablets for 1 year. All participants also continue their regular treatment for SLE. Participants are in the study for a bit longer than 1 year. During this time, they visit the study site regularly. Doctors check the participants' health and take note of any unwanted effects. They also compare the results between the groups to see if the treatment works.	Lupus	Phase 2	À vérifier	United States, Argentina, Australia, Brazil, Bulgaria, China, Colombia, Croatia, Germany, Hungary, India, Japan, Mexico, Netherlands, Poland, Romania, Serbia, South Africa, Spain, Taiwan, …	À vérifier
VicadrostatThis study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.	Hypertension	Phase 3	À vérifier	United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, …	À vérifier
NerandomilastThis study is open to adults aged 18 and older who have a condition known as active idiopathic inflammatory myopathy (IIM) or myositis. People can participate if they have a specific type of myositis. The purpose of this study is to find out whether a medicine called nerandomilast improves IIM symptoms. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take nerandomilast or placebo twice a day for 1 year. Participants are in the study for about 1 year and 2 months. During this time, they visit the study site at least 16 times. During this time, doctors regularly check the participant's health, IIM symptoms, and take note of any unwanted effects. Participants fill in questionnaires about their IIM symptoms and how IIM impacts their quality of life. The results are compared between the 2 groups to see whether the treatment works.	Myopathies	Phase 3	Immunomodulation + Traitement symptomatique	United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Romania, Serbia, …	À vérifier
BIIL 284 BSTo evaluate the effect of multiple doses of BIIL 284 BS on the pharmacokinetics of a single dose of theophylline.	SEP	Phase 1	À vérifier		À vérifier

Essais cliniques

6

Molécule	Indication / population	Phase	NCT	Titre	Statut
BIIL 284 BS	SEP	Phase 1	NCT02273440	Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers	COMPLETED
Nerandomilast	Myopathies	Phase 3	NCT07789015	VERANDA™-IIM — A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies	NOT_YET_RECRUITING
Vicadrostat	Hypertension	Phase 3	NCT07064473	EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease	RECRUITING
BI 3000202	Lupus	Phase 2	NCT07409181	A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)	RECRUITING
Empagliflozin	Alzheimer	Phase 2	NCT07756294	REVITAA-ALZ — Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease	NOT_YET_RECRUITING
Telmisartan	Hypertension	Phase 3	NCT00274118	DETAIL Study: Diabetes Exposed to Telmisartan and Enalapril	COMPLETED

Publications

4

Molécule	Indication / population	Titre	Journal	Date
enalapril		Sacubitril/Valsartan versus Enalapril or Losartan at Maximum Doses in Heart Failure with Reduced Ejection Fraction: Real-World Data.	Arquivos brasileiros de cardiologia
enalapril		Enalapril, Atenolol, Alendronate and DRESS Syndrome - A Case Report.	Acta dermato-venereologica
enalapril		High-molecular-weight hyaluronic acid promotes the protective axis of the renin-angiotensin-aldosterone system in human dermal fibroblasts.	Biochemical and biophysical research communications
enalapril		Scleroderma Renal Crisis and Posterior Reversible Encephalopathy Syndrome Triggered by Non-steroidal Anti-inflammatory Drugs.	Internal medicine (Tokyo, Japan)